Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508104 · ClinicalTrials.gov registry record · Phase 1
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by University of Cincinnati.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01508104: Clinical Trial Phase 1 study, sponsored by University of Cincinnati.
NCT01508104 is a Phase 1 study that was terminated before completion, run by University of Cincinnati. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01508104, a Phase 1 study, was terminated before completion, sponsored by University of Cincinnati.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to determine the effects good or bad of combining BEZ235 along with Everolimus to determine if it is a safe treatment for patients with advanced cancers of different types.
Interventions
- DRUG Everolimus
- DRUG BEZ235
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Why NCT01508104 stopped before completion
NCT01508104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01508104 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01508104 about?
NCT01508104 is a clinical study titled "Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors". The purpose of this clinical trial is to determine the effects good or bad of combining BEZ235 along with Everolimus to determine if it is a safe treatment for patients with advanced cancers of different types.
What is the current status of trial NCT01508104?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2012-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01508104?
The interventions under investigation include: Everolimus (DRUG), BEZ235 (DRUG).
Who is sponsoring clinical trial NCT01508104?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01508104's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia